Krishnan Krish S, who serves as President and Chief Executive Officer of Krystal Biotech, Inc. (NASDAQ: KRYS), sold 23,870 shares of the company's common stock on March 4, 2026. The aggregate proceeds from those disposals were approximately $6.58 million.
The dispositions were completed across multiple transactions with per-share prices ranging from $257.3131 to $266.555. One recorded sale consisted of 483 shares at $257.3131, generating $124,282 in proceeds. Additional transactions included lots of 470 shares, 1,377 shares, 3,128 shares, 2,962 shares, 2,380 shares, 2,043 shares, 8,798 shares, 2,439 shares and 920 shares sold at prices between $258.3795 and $266.555, collectively bringing in $6,454,882.
After these sales, Krishnan's direct ownership stands at 1,475,253 shares of Krystal Biotech common stock. He also retains indirect holdings of 90,000 shares through the Krishnan Spousal Trust and another 50,000 shares through the Krishnan Family Trust.
The transactions were carried out under a Rule 10b5-1 trading plan that Krishnan adopted on September 4, 2025. That plan began executing on December 4, 2025, and is set to terminate on December 4, 2026, unless it is ended earlier in accordance with its terms.
At the time of the reported sales, KRYS was trading at $253.69, reflecting a 7.96% decline over the prior week. Over a longer interval, the shares have gained 68.82% in the past six months.
Analytical coverage cited in relation to the share price indicates a Fair Value of $293.35 per share according to InvestingPro, which places KRYS on a Most Undervalued list based on that estimate. The company's financial health score referenced in that analysis is labeled "GREAT" with a numeric value of 3.7.
Separately, Krystal Biotech reported fourth-quarter 2025 results that surpassed analyst expectations. The company recorded earnings per share of $1.70, above a projected $1.58, and reported revenue of $107.1 million, ahead of the anticipated $106.16 million. These results were noted as stronger than forecasts and were cited in the context of investor reception to the company’s recent performance.
The information above reflects the transactions announced and the financial metrics reported. The trades were explicitly executed under the parameters of the previously established Rule 10b5-1 plan, and the company’s quarter-end results and InvestingPro valuation were reported as described.
Clear summary
Krishnan Krish S sold 23,870 shares of Krystal Biotech on March 4, 2026, through multiple trades priced between $257.3131 and $266.555 per share, yielding approximately $6.58 million. The sales were executed under a Rule 10b5-1 plan adopted on September 4, 2025. Post-sale holdings include 1,475,253 shares directly and indirect holdings of 90,000 and 50,000 shares through two trusts. KRYS shares traded at $253.69, while InvestingPro lists a Fair Value of $293.35 and a financial health score of 3.7. Krystal Biotech also reported Q4 2025 EPS of $1.70 and revenue of $107.1 million, both above expectations.